Clinical Trial

Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors

Terminated Early Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Strategic Portfolio Decision
Summary
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of ALPP CAR-T cells in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-07; most recent amendment 2026-01-26.
Status change: Recruiting → Terminated 2026-01-26
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT07123493
Lead Sponsor Haifeng Qin
Conditions Recurrent or Metastatic Solid Tumors With Positive ALPP
Enrollment 1 participants
Start Date 2025-08-28
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-28